Molecular (nucleic acid)-based diagnostics tests have many advantages over immunoassays, particularly with regard to sensitivity and specifi city. Most on-site diagnostic tests, however, are immunoassay-based because conventional nucleic acid-based tests (NATs) require extensive sample processing, trained operators, and specialized equipment. To make NATs more convenient, especially for point-of-care diagnostics and on-site testing, a simple plastic microfl uidic cassette ("chip") has been developed for nucleic acidbased testing of blood, other clinical specimens, food, water, and environmental samples. The chip combines nucleic acid isolation by solid-phase extraction; isothermal enzymatic amplifi cation such as LAMP (Loop-mediated AMPlifi cation), NASBA (Nucleic Acid Sequence Based Amplifi cation), and RPA (Recombinase Polymerase Amplifi cation); and real-time optical detection of DNA or RNA analytes. The microfl uidic cassette incorporates an embedded nucleic acid binding membrane in the amplifi cation reaction chamber. Target nucleic acids extracted from a lysate are captured on the membrane and amplifi ed at a constant incubation temperature. The amplifi cation product, labeled with a fl uorophore reporter, is excited with a LED light source and monitored in situ in real time with a photodiode or a CCD detector (such as available in a smartphone). For blood analysis, a companion fi ltration device that separates plasma from whole blood to provide cell-free samples for virus and bacterial lysis and nucleic acid testing in the microfl uidic chip has also been developed. For HIV virus detection in blood, the microfl uidic NAT chip achieves a sensitivity and specifi city that are nearly comparable to conventional benchtop protocols using spin columns and thermal cyclers.
Introduction
On-site detection of pathogens and other disease markers can improve the quality and lower the costs of health care [ 1 -10 ] . Portable on-site tests can also monitor the safety of food [ 11 , 12 ] and water supplies [ 13 ] . Clinical specimens can be processed in credit-card sized, plastic microfl uidic cartridges ("chips") that can be coupled to cell phones and other portable devices for detection, data analysis, and communications. In particular, a cell phone camera can be used to detect fl uorescent signals such as used to monitor the production of amplicons during the enzymatic amplifi cation process. This "lab-on-a-chip" technology provides for Point-of-Care (POC) diagnostics and serves as crucial enabling technology for mobile health care (mHealth). For example, the smartphone will transmit the test results to the patient's medical fi les, to the health provider, and, when appropriate and/or required by law, to public health offi cials. Based on the test results, the smartphone application could download instructions from the cloud to guide the patient. The health provider can contact a pharmacy and order prescriptions, provide additional guidance remotely, and encourage/ discourage an offi ce visit as appropriate.
This chapter describes the development of a microfl uidic cassette for nucleic acid based pathogen assays (with specifi c application to HIV viral load testing), and which is compatible with cell phone-based end-point detection of fl uorescence signals generated in real-time enzymatic amplifi cation of a pathogen target. The approach and methods reported here are suffi ciently generic and can be readily adapted to other POC diagnostics applications.
Broadly, in vitro bioanalytical methods can be classifi ed into three categories: (1) immunoassays that rely on specifi c antigenantibody binding (or analogous protein interactions) for isolation and labeling of analytes such as antibodies and/or antigens;
(2) nucleic acid-based ( molecular ) tests (NATs) that utilize sequence-specifi c nucleic acid hybridization, and for which the sensitivity can be greatly enhanced by enzymatic amplifi cation; and (3) cell-based methods incorporating cell fractionation and sorting, selective labeling, and/or cytometry which are often amenable to target amplifi cation via cell culturing. Most existing rapid (<hour), on-site test devices are based on immunoassays [ 14 , 15 ] since NATs are comparatively complicated and culturing and other cell-based methods are time-consuming.
Immunoassays are operationally simple because they are tolerant of sample heterogeneity and require few, if any, sample preparation and processing steps. Immunoassays can be performed with raw or minimally processed specimens such as blood, urine, saliva, cell culture, tissue, water, and environmental samples. For example, the lateral fl ow (LF) strip format offers an elegant, simple, and inexpensive implementation of immunoassays [ 16 ] . LF strip immunoassay tests, such as home pregnancy tests and drugs-of-abuse tests, are widely available.
Nucleic acid tests (NAT), also known as molecular assays, have a crucial advantage over immunoassays in that nucleic acids can be amplifi ed in vitro by sequence-specifi c enzymatic reactions, thus facilitating highly sensitive detection. A single target DNA molecule can be replicated a billion times within an hour. The specifi city of the test can be tailored by appropriate primer design. Typically, nucleic acid-based tests offer much greater (often 1,000-fold or more) sensitivity and specifi city than immunoassays. Nucleic acid-based tests can also provide information that cannot be readily obtained with immunoassays such as discrimination between drug-susceptible and drug-resistant pathogens and the identifi cation of genes and gene transcription profi les. Despite their many advantages, molecular assays are still not commonly used at the point of care and are generally restricted to centralized laboratories since nucleic acidbased tests typically require elaborate sample processing to release, isolate, and concentrate the nucleic acids and remove substances that inhibit enzymatic amplifi cation. Conventional nucleic acid testing requires benchtop equipment such as centrifuges, water baths, thermal cyclers, and gel readers; cold storage for labile reagents; dedicated lab areas and hoods to avoid contamination, and highly trained personnel. Moreover, for molecular analysis of blood specimens, cell-free plasma is preferred. The use of plasma instead of whole blood in NATs avoids problems associated with inhibitors (such as hemoglobin in red blood cells) [ 17 -19 ] , clogging of fi lters or porous membranes with cells and cell debris, and complications in interpretation of results related to nucleic acids associated with white blood cells [ 20 ] . The plasma is typically separated from whole blood by centrifugation. However, such and similar plasma extraction adds an extra processing step to NAT, further burdening point of care (POC) applications.
The objective of microfl uidics implementations of nucleic acid tests is to make NAT almost as easy-to-use as LF strip test devices. As an illustration, we describe a single-use (disposable), plastic, microfl uidic cassette or cartridge ("chip") that hosts fl uidic networks of conduits, reaction chambers, porous membrane fi lters, and inlet/outlet ports for sample processing and analysis. The sequential steps of sample metering, lysis of the pathogen target, NA isolation, reverse transcription (for RNA targets), enzymatic amplifi cation primed with target-sequence oligos, amplicon labeling, and detection are integrated in the microfl uidic chip. Fluid actuation and fl ow control, temperature control, and optical detection are provided by supporting instrumentation. Completely automated operation (without any human intervention) is feasible. Many microfl uidic NAT devices [ 21 -23 ] , including our earlier prototypes [ 24 -27 ] , utilize PCR (polymerase chain reaction) for nucleic acid amplifi cation. For example, Chen et al. [ 26 ] describe a microfl uidic cassette for PCR-based nucleic acid detection. The palm-sized cassette mates with a portable instrument [ 28 ] that provides temperature regulation using thermoelectric elements, solenoid actuation of pouches and diaphragm valves formed on the chip for fl ow control and pumping, and LED/photodiode detection of amplifi cation products labeled with an intercalating fl uorescent dye. The time needed from sample loading to obtaining test results is typically less than 1 h.
Although PCR technology is highly developed and PCR primers sequences are available for many targets, PCR is not optimal for on-site applications. PCR requires precise (±1 °C or better) temperature control and rapid (>5 °C/s) temperature ramping, which complicates implementation and increases the cost of instrumentation. The high temperatures (~95 °C) required for PCR places demands on chip design, necessitating strong bonding of chip components to withstand the pressure of the heated reaction mixture due to expanding trapped air and thermal expansion of the liquid phase and tight sealing of the amplifi cation chamber to avoid evaporation. As an alternative to PCR, isothermal amplifi cation methods are much easier to implement in on-site applications. Constant-temperature operation lowers energy consumption and even allows the use of small-scale exothermic chemical reactions for heating without a need for any electric power [ 29 ] . Thus, a considerable simplifi cation in chip design and operation is realized with isothermal amplifi cation methods [ 30 -34 ] that require, depending on the amplifi cation scheme, an incubation temperature ranging from 40 to 65 °C. Examples of isothermal amplifi cation include Loop-mediated AMPlifi cation (LAMP) to detect DNA targets [ 35 ] , one-step reverse transcription (RT) with cDNA LAMP (RT-LAMP) to detect RNA targets [ 36 -38 ] , Nucleic Acid Sequence Based Amplifi cation (NASBA) [ 39 , 40 ] , Recombinase Polymerase Amplifi cation (RPA) [ 41 , 42 ] , and helicase-dependent amplifi cation (HDA) [ 43 -45 ] . Tests using isothermal amplifi cation are typically faster than PCR (roughly, 30 min vs. 60 min). Also, LAMP appears to be more robust than PCR. It is more tolerant of temperature variations and less susceptible to the adverse effects of inhibitors [ 46 ] . In this chapter, we focus on LAMP. We have, however, successfully tested our chips with NASBA and RPA (results not shown) and obtained comparable results to the ones obtained with LAMP.
To streamline sample processing and fl ow control, we use "multifunctional" amplifi cation reactors that incorporate porous fl ow-through membranes for immobilization of nucleic acids [ 47 , 48 ] . A disc-shaped silica-or cellulose-based membrane is embedded in the chip at the inlet of each reaction chamber. Nucleic acid capture, washing, amplifi cation, and detection are all combined in a single chamber that houses the NA binding membrane. The target nucleic acid captured on the membrane serves as a template for amplifi cation, thus obviating the need for a separate membrane elution step (as done in spin column formats), and thereby simplifying chip design and fl ow control. Multiple amplifi cation reactors can be accommodated in the same chip ( Fig. 1 ) for concurrent detection of several targets, as well as calibration reactions, and positive and negative controls.
The lab-on-a-chip format can facilitate autonomous point-ofcare molecular diagnostics with various levels of automation, instrumentation, and functionality. For more convenient use, the chips can be preloaded with lyophilized amplifi cation reagents [ 49 -53 ] . During chip assembly, the LAMP reagents (enzymes, primers, dyes, salts) are measured and mixed in correct proportions and pipetted into the chip amplifi cation chamber, dried by sublimation, and coated with a low-melting point (~55 °C) paraffi n wax layer [ 52 ] . The chip is then sealed with a capping layer. The wax encapsulation protects the pre-stored reagents when the sample and wash solutions fl ow through the amplifi cation reactor. When the chamber is fi lled with water and heated to the LAMP incubation temperature (~65 °C), the wax coating melts, just in time, and releases the LAMP reagents to amplify the target NAs captured on the membrane.
For brevity, we describe in this chapter a manually operated NAT module. The sample and reagents are loaded into the chip by pipetting in the appropriate sequence. This manually operated version realizes only some of the advantages of microfl uidic systems. For a commercially viable system, the reagents will be prestored in the chip and the fl uid delivery automated. The module described here is, however, a substantial step towards the ultimate goal of fully automated operation. We describe the design, fabrication, and operation of the multifunctional reactor module. As a representative application, we describe the detection of an RNA virus (HIV) in blood plasma samples. Adaptations of the chip and protocol for other targets and applications are comparatively minor. We have used approaches similar to the one reported here for the detection of lambda phage in water, Gram-positive bacteria ( B. cereus ) [ 24 ] and gram-negative bacteria ( Salmonella ) in buffer, E. coli in urine and stool samples, and HIV virus in saliva [ 25 ] , and for genotyping malaria-transmitting mosquito subspecies using insect tissue [ 48 ] . The chips, with modifi cations, can also be used for gene profi ling as may be needed for cancer screening [ 54 ] . To accommodate blood-based samples, we describe a simple uninstrumented fi ltration device for separating plasma from whole blood. The extracted plasma is then subjected to a chemical lysis step to solubilize nucleic acids from viral or bacterial pathogens in the extracted plasma. The plasma-derived lysate is then loaded into the microfl uidic chip for assay of a sequence-specifi c nucleic acid biomarker.
Materials
Materials used include: 5. Polyimide-based, thin fi lm heater (HK5572R7.5L23A, Minco Products, Inc., Minneapolis, MN).
6. DC power supply (e.g., Model 1611, B&K Precision Corporation, CA).
Nucleic Acid binding phases:
(a) Silica-based phases: Whatman™ GF/F borosilicate glass fi ber fi lter paper (0.42 mm thick, 0.7 μm pore size), or (b) Cellulose-based membranes (Whatman FTA™ paper: 3MM Whatman cellulose fi lter paper, 0.5 mm thick, with dried Tris-HCl, EDTA, and SDS, which can be washed off the FTA paper before mounting in the chip).
8. Harris Unicore™ (2 or 3-mm diameter, Ted Pella, Inc., Redding, CA) for cutting discs of binding phase for insertion in chip.
9. Commercial kits with reagents (binding/lysis buffer, wash buffers, elution buffers) for isolation of nucleic acids:
(a) Qiagen Blood and Tissue kit (Valencia, CA).
(b) Roche HighPure™ Viral RNA kit or Qiagen QIAamp ® kit were used for RNA isolation.
(c) Elution buffer: Tris-acetate EDTA (TAE) buffer (10×) (Sigma-Aldrich).
Enzymatic Amplifi cation Kits
(a) Loopamp™ DNA amplifi cation kit (Eiken Chemical Co. Ltd.,Tochigi, Japan).
(b) RPA kit (TwistDX, Cambridge, UK), and the (c) NASBA kit (Biomérieux, Durham, NC).
11. RNase inhibitor (Ambion ® , Life Technologies) for amplifi cation reactions with the reverse transcription steps.
Fluorescent dyes for nucleic acid detection:
(a) SYTO-9 Green (Invitrogen Corp. Carlsbad, CA) or (b) EvaGreen (Biotium, Hayward, CA).
Positive HIV controls of known virus concentration
(Acrometrix ® , Benecia, CA).
14.
Published LAMP primer sets [ 38 ] , HPLC purifi ed (e.g., custom synthesized by Sigma-Aldrich).
(Suggested vendors are included for convenience, but comparable substitutions are generally permissible.)
Methods
The microfl uidic chips ( Fig. 1 ) are fabricated in clear (transparent) plastic materials as bonded laminates. We have tested three different thermoplastic polymers: polycarbonate (PC), acrylic (PMMA), and cyclic olefi n copolymer (COC) ( Table 1 ). The chips have been rapidly prototyped using computer-aided design (CAD) and computer-aided manufacturing software (SolidWorks™, MasterCAM™, or AutoCAD™). The 0.1-1-mm thick plastic sheets are cut with a computer-controlled (CNC) milling machine (e.g., Haas Offi ce Mill OM-1, Haas Automation, Oxnard, CA) or with a CO 2 laser (e.g., Universal Laser Systems, Scottsdale, AZ, 30-50 W power) to defi ne the microfl uidic circuit(s) and other features ( Fig. 2 ) . Chip fabrication and bonding methods for these materials are discussed in more details in references [ 55 -62 ] . The smallest feature size is the channel width, which is ~800 μm. For acrylic-based chips, the component layers are bonded with a weak solvent such as acetonitrile. These polymer materials exhibit low surface adsorption and usually do not require any special surface treatments; however, dynamic surface passivation with BSA (bovine serum albumin, 1-2 %), PVP-40 (polyvinylpyrrolidone 40), or Autofl uorescence associated with various chip materials has been characterized [ 67 ] . We note that the use of PCR-compatible sealing tapes for sealing the chamber avoid any unwanted adsorption of bonding solvent on the NA binding membrane. The chip shown in Fig. 1 [ 47 , 48 ] . The top PMMA fi lm was solvent-bonded with acetonitrile at room temperature. Residual solvent was removed by overnight heating at 50 °C. The solvent bonding can be effected by stacking and aligning the layers and running a bead (~5-10 μl) of solvent around the periphery of the stack using a pipette. The solvent wicks into the interface between adjacent layers and forms a strong bond after about 10 min ( see Note 1 ).
Chip Design and Fabrication
The experimental setup for on-chip LAMP amplifi cation and end-point fl uorescent detection is shown in Fig. 3 . Briefl y, the resistive heating system consists of a chip support equipped with a fl exible, polyimide-based, thin fi lm heater (HK5572R7.5L23A, Minco Products, Inc., Minneapolis, MN) and a type T thermocouple (Omega Engineering, each wire 75 μm in diameter, and a junction diameter of 170 μm). The thermocouple junction was placed at the interface between the heater and the chip. The chip, once fi lled with the LAMP master mix, was fi xed to the chip support with a double-sided adhesive tape, allowing the reactors to form a good thermal contact with the thin fi lm heater. The heater was powered by a DC power supply (Model 1611, B&K Precision Corporation, CA). The power supply was adjusted to maintain the reactors at 63 ± 0.5 °C. Although the LAMP process is fairly forgiving to temperature variations, in fi eld applications, it would be necessary to use a closed-loop thermal controller to accommodate operation over the broad range of ambient temperatures that may be encountered in various regions and times.
The chip features solid-phase extraction to isolate nucleic acids from samples. The chip described here is based on the method of Boom et al. [ 68 -70 ] using chaotropic salts to promote selective binding of NAs to a (silica-based) solid phase, and as adapted by others [ 71 -77 ] for microfl uidic implementation. Several types of porous membranes for the nucleic acid (NA) binding phase have been employed, including "silica" (Whatman™ GF/F borosilicate glass fi ber fi lter paper, 0.42 mm thick, 0.7 μm pore size) and cellulose-based membranes (Whatman FTA™ paper: 3MM Whatman cellulose fi lter paper, 0.5 mm thick, with dried Tris-HCl, EDTA, and SDS, which can be washed off the FTA paper before mounting in the chip). Both these membranes can be readily cut to the desired shape and size (e.g., 1.5 mm diameter) using a hole punch (Harris Unicore™, Ted Pella, Inc., Redding, CA), and then inserted into the chip during its assembly. Other membranes such as nanoporous alumina (Whatman Nanopore™) can also function as nucleic acid binding phases, but are diffi cult to cut to size and mount in the chip due to their brittleness [ 52 , 53 ] ( see Note 2 ). During development stages, reagents from commercial nucleic acid isolation kits can be used, or alternatively, NA isolation can be done with generic components as specifi ed in Tables 2 , 3 and 4 . DNeasy™ Blood and Tissue kit, which includes AL (lysis and binding) buffer and AW1 and AW2 ethanol-based wash buffers, was purchased from Qiagen Inc. (Valencia, CA). Roche HighPure™ Viral RNA kit or Qiagen QIAamp ® kit were used for RNA isolation. The Loopamp™ DNA amplifi cation kit was obtained from Eiken Chemical Co. Ltd. (Tochigi, Japan). The RPA kit was supplied by TwistDX (Cambridge, UK), and the NASBA kit was from Biomérieux (Durham, NC). RNase inhibitor (Ambion ® , Life Technologies) was added to the amplifi cation reactions with the reverse transcription steps. SYTO-9 Green (Invitrogen Corp. Carlsbad, CA) or EvaGreen (Biotium, Hayward, CA) were used as [ 38 ] .
Use of Nucleic Acid Binding Phases for Isolation of Nucleic Acids

Reagents
Fluorescence detection of the amplifi cation products requires a nucleic acid binding dye [ 78 ] or a molecular beacon [ 79 ] as a reporter of amplicons. For real-time detection, the dye or beacon is included in the amplifi cation reaction mix. The intercalating dye nonspecifi cally binds the double-stranded amplifi cation product as well as sample "background" DNA co-isolated with the target, and any artifacts such as primer-dimers or misprimed amplicons. The fl uorescence emission signal monotonically increases as more amplicons are produced. Molecular beacons work by hybridization of a doubly functionalized (fl uorophore and quencher) oligo probe to the amplicon, such that quenching of the fl uorophore by the otherwise proximal quencher is relieved, and a fl uorescence signal proportional to amplicons concentration is produced. Molecular beacons generally produce weaker fl uorescence than intercalating dyes but are less prone to nonspecifi c targeting. The selection of a particular reporter determines the excitation and emission wavelengths of the fl uorescence, which informs the choice of light source, detector spectral response, spectral optical fi lters (if needed), and spectral transparency range of the chip material. A few common fl uorescent reporters that can be used in these devices are listed in Table 5 . These dyes are selected for their known compatibility with enzymatic amplifi cation, i.e., they are not strong inhibitors of PCR or isothermal amplifi cation at the recommended dye concentrations. Too high a dye concentration can, however, inhibit amplifi cation. The autofl uorescence of the plastic chip material creates a background signal (see below). The NA-binding membrane material also fl uoresces and must be excluded from the detector's fi eld of view. The active area of the chip for fl uorescence detection can be framed with opaque (non-fl uorescing) tape. We have also successfully used molecular beacon probes based on fl uorescence resonance energy transfer (FRET) to measure amplicon production.
Fluorescent Reporters
On-chip real-time detection of amplicons requires: (1) an excitation light source with spectral emission that matches the strong absorption band of the fl uorophore; (2) the transmission of the excitation
Real-Time Detection
light into the amplifi cation chamber(s); (3) fi ltering out the excitation spectra to prevent its detection; and (4) the detection of the (longer wavelength) light emitted from the reaction chamber with a detector having appropriate spectral responsivity. Various approaches to fl uorescence detection on chips are feasible [ 80 -85 ] .
To detect the fl uorescence signal on the chip, we have used either (1) a commercial compact fl uorometer such as the Qiagen ESE Fluo-Sens reader (Model ESE Model ESML 10-MB-3007 with 520 nm excitation and silicon photodiode detector); (2) a portable (palm-sized) fl uorescence microscope (DinoLite™ Model AM4113T-GFBW) with seven built-in blue LEDs for illumination, an emission fi lter with a 510-nm wavelength cutoff, a CCD camera detection, and a USB connection; and (3) a cell phone camera in conjunction with LED excitation and an appropriate fi lter. Both the Qiagen ESE reader and the portable fl uorescence microscope have their own excitation sources and optical fi lters and are suitable for detection with SYTO Green, SYBR Green, and EVA Green dyes. The Qiagen ESE reader can view only one reactor at a time and must be mounted on a scanner when the chip houses an array of reactors. In contrast, the USB-based microscope and the CCD camera can monitor multiple reactors simultaneously and do not require scanning. Both the USB-based microscope and the smartphone camera require imaging software (e.g., ImageJ ® or MATLAB ® ) to quantify and process the detected signal. Given the ubiquity of cell phones even in Third World countries, the use of a cell phone is an attractive option. By taking advantage of mobile devices, we can reduce the cost of the instrumentation needed for the diagnostic devices while at the same time providing the ability of transferring test results wirelessly to a centralized depository for archiving, analysis, and public health monitoring. For smart cell phone-based detection, one can illuminate the edge of the chip with blue light LED or laser. The light is guided into the reaction chambers through the transparent chip material. Lensing and waveguide structures can also be formed in the chip during the microfl uidic circuit machining process to attain more uniform excitation of the reactor array [ 86 ] . LEDs with emission wavelengths of 450-500 nm are needed to excite many of the common dyes (Table 5 ). Unfortunately, many nominally "blue" LEDs have a signifi cant green component that overlaps with the emission of the fl uorophore. To minimize interference from the excitation source, suitable bandpass and longpass colored glass or interference coating optical fi lters (Thor Labs, Newton, NJ or Edmund Scientifi c, Barrington, NJ) must be used to block excitation light from the detector. For example, when using blue emission (450-500 nm), we employed a Thor Labs LED465E fi lter (2.5-mm diameter, nominal emission peak at 465 nm with spectral FWHM, full-width half maximum of 50 nm). Note that the plastic chip materials are not very transmissive for UV (for dyes such as EtBr or calcein), so waveguiding light into the edge of the chip may not be always feasible. As an alternative to fl uorescence-based detection, several colorimetric and turbidity assays have been reported for isothermal amplifi cation [ 87 , 88 ] .
For the analysis of blood samples, plasma is fi rst separated from whole blood. Traditionally, plasma is separated from blood by centrifugation. Centrifugation is, however, inappropriate for on-site applications. As an alternative means, we developed a passive, lowcost, pump-free separator (Fig. 4 ) that utilizes both sedimentation and fi ltration to extract plasma from whole blood [ 89 ] . The sedimentation process reduces the concentration of the cells in the blood that is then fi ltered through an asymmetric plasma separation membrane (polysulfone, Vivid™ GR, Pall Corp., Port Washington, NY). Red cells, white cells, and platelets are trapped without lysis in the large pores on the upstream side of the membrane. The plasma outfl ows through the smaller pores on the membrane's downstream side. The separated plasma is collected with a pipette. The plasma separation module was tested by extracting about 275 μl of plasma from 1.8 ml of whole blood with known titer of HIV, in less than 7 min, using only a pipette to load and retrieve the sample. The plasma was then subjected to lysis to solubilize target nucleic acids from the virus (or bacteria) of interest, and processed in our microfl uidic chip as described in the next section.
Plasma Extraction from Whole Blood Using a Filtration Module
We focus on the operation of a microfl uidic module that integrates nucleic acid isolation, amplifi cation, and detection using the multifunctional amplifi cation reactor described above. For clarity and brevity, only manual operation of the chip is described. The sample is lysed off-chip by mixing it with a chaotropic salt (guanidinium chloride) and other optional lysing agents (e.g., detergents, proteinase K, lysozyme). The lysis deactivates any infectious agents in the sample as well as nucleases that might degrade target NAs. The lysate is then pipetted through the membrane and the reaction chamber ( see Note 3 ). The chaotropic salt promotes binding of the nucleic acids to the membrane. The membrane-bound nucleic acids are then washed with buffer to remove debris and inhibitors. In the normal mode of solid-phase extraction (i.e., spin column), the captured nucleic acids are eluted from the membrane into the amplifi cation chamber with a low-salt, pH-neutral buffer. In contrast, in our device, we simplify the process by forgoing a separate elution step. The membrane is sited at the inlet of the amplifi cation chamber and is in contact with the amplifi cation reaction mixture. The membrane-bound nucleic acids serve directly as templates for amplifi cation. An important advantage of this confi guration is that the sample volume (the amount of lysate fi ltered through the membrane) is largely decoupled from the volume of the amplifi cation reaction. Nevertheless, there is an optimum membrane size for a given sample volume and amplifi cation chamber size. The membrane must be large enough to capture a high fraction of the NA from the perfusing lysate, but not too large as to impede desorption of captured NA during amplifi cation. Also, the silicabased membrane material partially inhibits enzymatic amplifi cation. The cellulose-based FTA membrane shows a better compatibility with enzymatic amplifi cation, i.e., less inhibition of amplifi cation. We speculate that inhibition of amplifi cation by the membrane material results from irreversible adsorption of template, primers, and/or polymerase to the membrane since experience teaches that inhibition effects are reduced when the concentrations of these three components are increased in the reaction mix.
As an example of the chip operation, we describe the detection of HIV virus in blood. The various processing steps are depicted schematically in Fig. 5 . Plasma separated from whole blood was subjected to a chemical lysis step using a combination of chaotropic salts, detergents, and enzymes. Nucleic acids were isolated from the lysate by solid-phase extraction, and the purifi ed, concentrated, immobilized nucleic acids were subjected to sequence-specifi c
Chip Operation
enzymatic amplifi cation using targeted oligo primer sequences. The production of amplicon was then monitored by a DNA-binding fl uorescent dye (Fig. 6 ). Troubleshooting for Amplifi cation/ Detection Step: See Notes 4 -6 .
1. A blood sample laden with the suspected pathogen (e.g., HIV virus), ranging in volume from 100 μl to 1 ml (depending on the required limit of detection), is inserted into the plasma separator. The plasma separator utilizes a combination of fi ltration and sedimentation to separate the plasma from the blood.
2. Add 4 volumes of lysis/binding buffer to 1 volume of plasma (e.g., add 400 μl lysing buffer to 100 μl plasma) and incubate for 10 min at room temperature.
3. Optionally, add carrier RNA suspension (20 ng per sample) to the lysis buffer.
4. Pipette a volume of lysate (50-500 μl) into the chip, perfusing the membrane.
5.
Pipette 100 μl ethanol-based wash solution through the membrane, washing the membrane. 7. Dry the membrane to remove residual ethanol by aspirating or blowing dry air through inlet port with a 10-ml syringe.
Steps for a Blood Sample Molecular Analysis on a Chip
8. Inject amplifi cation mix (with correct proportion of enzymes, primers, nucleotides, salts, and dye) into the reactor as proportioned for volume of amplifi cation chamber. Flow the reaction mix through the membrane and fi ll the amplifi cation chamber.
9. Seal the chip inlet and outlet with PCR sealing tape.
10. For isothermal LAMP amplifi cation, incubate chip at 65 °C on a hotplate. (Use a "dummy" calibration chip with embedded thermocouple to adjust hotplate settings.) Foam rubber can be placed around the chip (with portal opening for camera) to reduce temperature fl uctuations from ambient room drafts.
11. Excite the fl uorescent dye and monitor the emission with either a fl uorometer or a camera. (optional) If desired, a melting curve can be constructed to verify that the melting temperature is consistent with the expected amplicons. Alternatively, the amplifi cation products can be removed from the reaction chamber and subjected to gel electrophoresis to verify that the size of the amplicons is consistent with expectations. As yet another option, instead of real time detection, the amplifi cation products (when the primers are appropriately functionalized) can be run on a lateral fl ow strip for end point detection.
Real-time fl uorescence emission intensity as a function of amplification time for a LAMP-based chip is shown in Fig. 6 . The curves correspond to samples spiked with different HIV virus concentrations and have a characteristic sigmoidal shape (similar to real-time PCR). The rapid increase in the fl uorescence intensity occurs sooner as the number of target copies in the sample increases [ 47 ] . In other words, the threshold time needed to observe emission intensity above background level can be correlated with the concentration of target copies in the sample (Fig. 6 , inset) . The threshold time is a linear function of the logarithm of the target concentration. By developing appropriate calibration curves, one can infer the unknown number of virus copies in a sample. The results indicate that our cassette's detection limit is smaller than 1,000 HIV copies/ml.
The microfl uidic module and protocol for nucleic acid isolation and amplifi cation described here are a convenient alternative to benchtop molecular assays. The microfl uidic device combines nucleic acid isolation typically done using commercial spin column kits with enzymatic amplifi cation and detection as conventionally done in Eppendorf tubes in a benchtop thermal cycler instrument. A sample can be processed in the microfl uidic chip in less than an hour. In several applications, such as analysis of an RNA virus in blood plasma, limits of detection comparable to benchtop assays (<1,000 virus particles per ml sample) have been realized. This "lab-on-a-chip" approach is attractive for processing of a small number of samples. More importantly, the microfl uidic module described here can serve as a component of an autonomous, por- (c) Inhibitors persist . The solid-phase extraction process should generally remove inhibitors. Inhibitors may be intrinsic to the sample and/or to the chip due to residual bonding solvent left over in the chip or membrane or due to residual ethanol. Sample dilution will reduce the concentration of inhibitors and help mitigate the effects of sample inhibitors. Increasing membrane drying duration will help to remove any residual ethanol left over from the wash steps.
In the case of blood samples, anticoagulants (e.g., EDTA chelates Mg needed for polymerases) may interfere with the amplifi cation process. Proteinase K and other lysing agents may degrade polymerases, and unlike in PCR, there is no high temperature heating (>90 °C) in the isothermal amplifi cation process to inactivate nucleases and proteinases. If certain lysing agents are suspected of inhibiting amplifi cation, their necessity in the protocol should be reconsidered, or else more rigorous washes (repetitions and greater total wash buffer volume) should be used to enhance their removal.
(d) Incorrect or suboptimal incubation temperature . Temperature overshoots of 10 °C over the recommended incubation temperature can degrade enzymes. Verify there is no overshoot in temperature during heat-up which may abolish enzyme activity. Also, too low a temperature will reduce amplifi cation effi ciency.
5.
Limit of detection in the chip is signifi cantly lower than parallel benchtop assay. Possible causes:
(a) Non-optimal temperature control . Check amplifi cation reactor temperature with a calibration chip equipped with temperature sensor.
(b) Fluorescent dyes degraded . Dyes lose their fl uorescence over time due to bleaching and excessive freeze-thaw. Minimize exposure of dyes to light as much as possible. Dyes can be mixed with calibration DNA (such as gel marker ladders) and tested in chip with fl uorometer.
(c) Low NA yield . Add more carrier RNA to the sample to improve yield of on-chip NA isolation. Check NA yield: Assay nucleic acid captured on the NA binding membrane by eluting with 10-50 μl of warm (~50 °C) water or TE buffer, and measure (total) NA concentration and purity (260/280 ratio) with a spectrophotometer (e.g., Nanodrop™, Thermo Scientifi c, Wilmington, Delaware) or fl uorometer (TBS-380 with PicoGreen™ dye for DNA and RiboGreen™ dye for RNA, Turner Bio Systems, Sunnyvale, California). Since depending on sample matrix, (total) NA can range from hundreds of picograms to hundreds of nanograms, it is probably more meaningful to compare chip NA yields to spin-column yields of comparable samples.
6. Amplifi cation is detected for nominally negative samples/ controls. Possible causes include:
(a) Primer-dimer or nonspecifi c amplifi cation is creating a false signal . Run amplifi cation product on gel or produce a melting curve in a benchtop PCR to verify that the amplifi cation product has the expected size.
(b) Excessive incubation time may lead to the production of artifacts such as primer dimers. When using LAMP, limit the duration of the amplifi cation process to less than 45 min.
(c) Excess Mg results in nonspecifi c amplifi cation. Adjust Mg concentration according to manufacturer's protocol for amplifi cation. Note that EDTA and some other anticoagulants used in blood samples are chelators for Mg.
(d) Contamination from previous runs . Due to their very high effi ciency, the isothermal amplifi cation techniques are particularly sensitive to contamination. This problem affects the assay developers, not on-site users. As a precaution, we prepare reagents and load the chips in separate labs and use dedicated pipettes. Chips should be left sealed after amplifi cation to avoid the spreading of any amplicons. Gel electrophoresis of amplifi cation product creates an aerosol of amplicons, and so should be done as far away from the sample prep and test area as possible. Experience shows that molecular biology grade water is often the source of contamination. When you purchase primers, aliquot the primers (25-50 runs worth) and cold store separately (preferably in a distant lab) to avoid contaminating the entire primer batch. Unfortunately, once the lab area is contaminated with amplicons, it may prove diffi cult to alleviate, so constant diligence is strongly advised.
